The news story you are looking for has expired. A more recent related article is displayed below.

Sponsored Links

Protalix Said Late-Stage Study Of Gaucher Drug Uplyso Met Primary Goals (PLX)

Oct 15, 2009 (SmarTrend(R) News Watch via COMTEX) --

10/15/2009 - Protalix BioTherapeutics Inc. (NYSE:PLX) said Thursday that a late-stage study of its Gaucher drug, Uplyso, met its primary goals. The company said that the studies showed that patients taking Uplyso had significantly smaller spleen volume, which is a symptom of the disease. The study tested two doses of intravenous Uplyso on 31 patients and last nine-months. The patients in the trial receive a dose of the drug every two weeks and the doses were either 30 milligrams per kilogram of the patient's body weight, or 60 milligrams per kilogram. The company said that patients in both groups had lower spleen volume after six months of taking doses.

Write to Chip Brian at cbrian@tradethetrend.com

---------------------------------------------------------------------------------------------

SmarTrend analyzes over 5,000 securities simultaneously throughout the trading day and provides its subscribers with trend change alerts in real time. To get a free trial of our trading calls and maximize your trading results, please visit http://www.TradeTheTrend.com.

Get exclusive, actionable insight into how the market is expected to trend prior to market open with our free morning newsletter. Sign up at: http://www.TradeTheTrend.com/signup.html

Copyright (C) 2009 Comtex SmarTrend(R). All rights reserved

News Provided by COMTEX


Related terms: market, nyse, securities

Related Articles

Protalix Announces Positive Results on Gaucher Drug - Zibb.com
Oct 15, 2009
Protalix Announces Positive Results on Gaucher Drug Protalix BioTherapeutics (PLX) said today its treatment...result of the disease showed encouraging efficacy of the drug, Uplyso, as well as a high safety profile and low antibody formation...

Standard Register Reports Q3 Loss
Oct 28, 2009
...customer base, improving our cost structure, and creating the framework for our new market focused business units are the primary goals for 2009," stated Joe Morgan, president and chief executive officer. "Activities for the current quarter show that we...

Protalix’ Gaucher’s Therapy Demonstrated Positive Results in Phase III
Oct 15, 2009
...when it closed one of its plants due to viral contamination. Protalix’ trial met its primary endpoint, mean reduction in spleen volume after nine months compared with baselines in both 60 units/kg dose and in the lower 30 units/kg dose treatment groups...

Protalix Biotherapeutics's Gaucher Drug Meets Goal in Late-Stage Study
Oct 15, 2009
... Print Protalix Biotherapeutics's Gaucher Drug Meets Goal in Late-Stage Study 10/15/2009 Bookmark and Share...its primary endpoint, mean reduction in spleen volume after nine months compared with baselines...